Antithrombin Market Size (2022-2030) Worth US$ 776.1 Million| Growth Plus Reports

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Antithrombin Market Size (2022-2030) Worth US$ 776.1 Million| Growth Plus Reports

PR Newswire

NEW YORK, Aug. 19, 2022 /PRNewswire/ -- The growing use of antithrombin in conjunction with heparin, and the increased risk of diseases like sepsis, intravascular coagulation, and myocardial infractions, are the key drivers of the global antithrombin market. Additionally, the rising use of antithrombin-based diagnostic assays is spurring the demand for antithrombin agents. However, the rising usage of biologics and the high price of antithrombin drugs are limiting the global antithrombin market growth. According to the latest report published by growth plus reports titled "Antithrombin Market by Application (Therapeutics, Research, Diagnostics), by Source (Human, Goat Milk, Bovine), by Dosage Form (Lyophilized, Liquid) –Global Outlook & Forecast 2022-2030" antithrombin market is expected to clock US$ 776.1 million by 2030 with a CAGR of 3.90% between 2022 to 2030.

Growth Plus Reports Logo

Download Exclusive Sample of Report @

Excerpts from 'by Applications'

According to applications, the global antithrombin market is grouped into:

  • Therapeutics
  • Research
  • Diagnostics

The therapeutics segment has the largest revenue for antithrombins globally. Antithrombins are recommended for treatment in patients with congenital antithrombin deficiencies and when there is significant bleeding during surgery. These are also employed following operations to lessen blood clots. Deep vein thrombosis (DVT) and pulmonary embolism are more common diseases in which antithrombins are recommended. Other segments like research and diagnostics can also show growth in the forecast period. For instance, the increased diagnostic test for antithrombins is noted in diseases like deep vein thrombosis to monitor the number of blood clots.

Excerpts from 'by Source'

According to source, the global antithrombin market is segmented into:

  • Human
  • Goat Milk
  • Bovine

The goat milk segment has dominated the global market, due to high yielding, less gestation period makes goats well suited to perform recombinant DNA technology. The anticoagulant ATryn is the first biologic ever created by a genetically modified (GE) goat. Other segments like human and bovine are also expected to show growth in the forecast period due to factors such as it benefits from having a low antigenicity and not bearing the risk of viral transmission.

Report Scope & Segmentation:

Report Coverage


Market Size in 2021

USD 550 million

Revenue forecast in 2030

USD 776.1 million

Growth Rate

CAGR of 3.90% from 2022 to 2030

Base year for estimation


Forecast period


Segments covered

Application, Source, Dosage Form

Regional scope

North America, Europe, Asia Pacific, and the Rest of the World (ROW)


Ask here for customization @

Excerpts from 'By Region'

North America, Europe, Asia Pacific, and the rest of the world are the four geographic divisions that make up the global antithrombin market. The largest share of the global antithrombin market is held by North America. Increased incidences of heart disease are one of the elements behind this expansion. Strong blood coagulation inhibitors like antithrombins are crucial for treating illnesses connected to the myocardium. The European market is attributed by factors such as region's rapid technological advancement, high level of awareness, and rising medicine approvals. Due to the rise in coagulation-related diseases and the high number of patients undergoing heart surgeries encounter in their inflammatory systems, the Asia Pacific is also anticipated to show lucrative growth throughout the projected period due to improved healthcare infrastructure, increased research and development. 

Excerpts from 'Competitive Landscape'

Some of the prominent market players operating in the global antithrombin market are:

  • Gilead Sciences Inc
  • Strategic Developments
  • Bristol-Myers Squibb Company
  • Novartis International AG
  • Merck & Co
  • Shire Plc
  • Kedrion S.p.A
  • Scripps Laboratories Inc
  • Lee BioSolutions, Inc
  • Grifols S.A
  • SCL Behring

Table Of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trend (COVID-19 Perspective)
    2. Technological Trends
    3. Key Players & Competitive Positioning (2021)
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Therapeutic
    2. Research
    3. Diagnostics

TOC Continued..

Speak to analyst:

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020".

Manan Sethi
Director, Market Insights
Email: [email protected]
Phone no: +91 96545 76783
Follow Us: LinkedIn | Twitter


Cision View original content:

SOURCE Growth Plus Reports

Copyright CNW Group 2022

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).